Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

JPMorgan names Fresnillo as top gold mining pick

(Sharecast News) - JPMorgan has raised its target price for precious metals miner Fresnillo from 900p to 1,000p and named the stock its top pick among the EMEA-listed gold mining sector. The bank, which is 'overweight' on the EMEA gold mining sector as a whole, said Fresnillo was its preference given it is trading on a 3.5x enterprise value-to-EBITDA ratio at a 12% free cash flow yield.

"We expect management guidance on opex inflation at FY24 results (4 March) to further de-risk 2025/26E earnings forecasts," JPM said.

UK-listed Hochschild was also rated 'overweight' given its potential to re-rate as well.

The bank said it was reiterating its positive view on the sector, with shares having traded sideways since the start of November despite a 4% increase in the gold price.

Inflationary pressures, tariff uncertainty and geopolitical tensions should provide upside to prices over 2025, with gold expected to hit the year-end target of $2,950/oz sooner if tariffs risks are prolonged, up from new record of $2,869.68/oz on Wednesday morning.

"Although recent investor marketing indicates a bullish gold outlook is widely shared, there is less conviction or consensus on how to be positioned in the sub-sector. Thus, we still see a compelling entry point for the EMEA Gold Miners given they screen exceptionally cheap with >10% FCF yields and pose fewer operational risks following recent guidance updates."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.